Form 8-K - Current report:
SEC Accession No. 0001437749-24-029380
Filing Date
2024-09-17
Accepted
2024-09-17 16:22:21
Documents
15
Period of Report
2024-09-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20240917_8k.htm   iXBRL 8-K 30397
2 EXHIBIT 10.1 ex_724740.htm EX-10.1 52060
  Complete submission text file 0001437749-24-029380.txt   230336

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sava-20240913.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20240913_def.xml EX-101.DEF 11808
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20240913_lab.xml EX-101.LAB 15859
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20240913_pre.xml EX-101.PRE 12023
17 EXTRACTED XBRL INSTANCE DOCUMENT sava20240917_8k_htm.xml XML 2957
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 241304711
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)